Stocks and Investing
Stocks and Investing
Wed, October 23, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Phil Nadeau Maintained (BIIB) at Buy with Increased Target to $325 on, Oct 23rd, 2019
Phil Nadeau of Cowen & Co., Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $275 to $325 on, Oct 23rd, 2019.
Phil has made no other calls on BIIB in the last 4 months.
There is 1 other peer that has a rating on BIIB. Out of the 1 peers that are also analyzing BIIB, all agrees with Phil's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $250 on, Friday, June 28th, 2019
Contributing Sources